Bioatla Inc

NASDAQ BCAB

Data sourced from

and

Download Data

Bioatla Inc Dividend Payout Ratio for the Trailing 12 Months (TTM) ending March 31, 2024

Bioatla Inc Dividend Payout Ratio is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The dividend payout ratio measures the percentage of a company's net income that is distributed as dividends to shareholders. It is calculated by dividing dividends paid by net income. This ratio provides insights into the portion of earnings that is returned to shareholders in the form of dividends. A higher ratio indicates a larger proportion of earnings being paid out as dividends.

NASDAQ: BCAB

Bioatla Inc

CEO	Dr. Jay M. Short Ph.D.
IPO Date	Dec. 16, 2020
Location	United States
Headquarters	11085 Torreyana Road, San Diego, CA, United States, 92121
Employees	65
Sector	Healthcare
Industry	Biotechnology

Description

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

Key trends